Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

YO10 - Rectal Follicular Dendritic Cell Sarcoma

Date

23 Nov 2019

Session

Poster display session

Topics

Tumour Site

Soft Tissue Sarcomas

Presenters

Kripa Bajaj

Authors

K. Bajaj

Author affiliations

  • Medical Oncology Dept., Tata Memorial Hospital, 400012 - MUMBAI/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract YO10

Case summary

A 22y/female

No comorbidities

No family history of any malignancy

Presented with complaints of mass P/R from December 2014

Initially patient was on alternative medication with an opinion of hemorrhoids

In October 2015 in view of increased symptoms got evaluated and U/W Sigmoidoscopy and found to have growth

2/12/15 U/W Polypectomy

HPR S/O Follicular dendritic cell sarcoma with negative margins

21/12/15 CECT S/O no abnormality , though patient was planned for surgery with revision of margins opted for observation

July 2016 Patient is asymptomatic and on follow up found to have (USG and CT further) multiple liver metastases with Bx consistent with same.

Received 4# CHOP till 17/11/16

Dec 2016 CT S.O Increase in number and size of hepatic metastases

Started on Gemcitabine+Docetaxel 6# with interim assessment S.O partial response and further mainatined.

11/9/17 U.W RFA of Segment VIII of right lobe and Segment III of left lobe of liver.

Received 2# more Gemciatbine+Docetaxel till 20/10/17

November 2017 PET CT S/O Complete metabolic response and kept on observation

9/3/18 Evaluated for abdominal discomfort and S.O liver lesions in segment IVb and Segment V lesions

15/3/18 IVb and V lesion coiling was done and kept on observation

May 2018 Significant increase in number and size of lesions and was started on Tab.Capecitabine 500mg BD+Tab.Sorafenib 400mg BD

July 2018 Response assessment was done S/O increase in size of lesions with maximum lesion size increased from 3.9----->6 cms

Started on Tab.Pazopanib +Tamoxifen

October 2018 response assessment was done S/O Partial response with decrease in size and enhancement

27/12/18 U/W resection of liver IVb/V segments and Pazopanib+Tamoxifen were continued as an adjuvant from January 2019 to April 2019

Lost to follow up for 2 months and stopped medications from 2 months

13/6/19 Asymptomatic but CT S/O two new lesions in liver segment VII 2.1x 1.4cms and 1.2x1.2 cms were noted.

CURRENT STATUS : Restarted on Tab.Pazopanib 400mg BD and planned for RFA further

Clinical trial identification

Editorial acknowledgement

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.